🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. ACTILYSE, poudre et solvant pour solution injectable et perfusion, ACTILYSE, poudre et solvant pour solution injectable et perfusion, Metalyse 10,000 units powder and solvent for solution for injection, ACTILYSE, poudre et solvant pour solution injectable et perfusion, Metalyse 5 000 units (25 mg) powder for solution for injection

    Tour Hekla

    Acute ischaemic stroke due to basilar artery occlusion.

    phase 3 small molecule active

    1 trial

  2. ACTISOUFRE, solution pour pulvérisation nasale/buccale en flacon pressurisé, Actisoufre Placebo

    Laboratoire HRA Pharma

    rhinosinusitis not requiring antibiotic therapy, rhinopharyngitis not requiring antibiotic therapy, Acute rhinitis not requiring antibiotic therapy

    phase 3 small molecule active

    1 trial

  3. ADX-102 1% Topical Dermal Cream (reproxalap)

    Aldeyra Therapeutics

    Sjogren-Larsson Syndrome

    phase 3 small molecule completed

    1 trial

  4. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra Therapeutics

    Non-infectious Anterior Uveitis

    phase 3 small molecule completed

    1 trial

  5. ADX-2191 (intravitreal methotrexate 0.8%)

    Aldeyra Therapeutics

    Proliferative Vitreoretinopathy

    phase 3 small molecule completed

    1 trial

  6. AG-120/S95031 250mg film-coated tablet, Ivosidenib-matched Placebo Tablets

    The George Institute

    Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens

    phase 3 small molecule active

    1 trial

  7. AG-348

    Agios Netherlands B.V.

    Pyruvate Kinase Deficiency

    phase 3 small molecule completed

    2 trials

  8. AG10

    BridgeBio Oncology Therapeutics

    Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

    phase 3 small molecule terminated

    1 trial

  9. AK112 Injection

    Summit Therapeutics

    Non-Squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  10. ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Pembrolizumab, KEYTRUDA 25 mg/m

    Celltrion Healthcare Australia Pty Ltd

    Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  11. ALN-TTRSC04, Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam Netherlands B.V.

    Hereditary transthyretin-mediated amyloidosis with polyneuropathy

    phase 3 small molecule active

    1 trial

  12. ALPELISIB, ALPELISIB, ALPELISIB

    Ningbo Cancer Hospital

    PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previously treated with trastuzumab

    phase 3 small molecule active

    1 trial

  13. ALPELISIB, FULVESTRANT, ALPELISIB, Placebo to BYL719 50 mg film-coated tablet Light pink Placebo to BYL719 200 mg film-coated tablet Light red

    Novartis Pharmaceuticals

    Hormone receptor positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  14. ALVAC-HIV vCP1521 + AIDSVAX

    United Therapeutics Europe Ltd

    HIV Infection

    phase 3 mab completed

    1 trial

  15. ALXN 2040, ALXN 2040

    Alexion Europe SAS

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  16. ALXN1720 Placebo Product, Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  17. ALXN2060

    BridgeBio Oncology Therapeutics

    Symptomatic Transthyretin Amyloid Cardiomyopathy

    phase 3 small molecule completed

    1 trial

  18. AMG 133, AMG 133, AMG 133, AMG 133, Placebo for Maridebart cafraglutide

    Amgen

    Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight

    phase 3 small molecule active

    1 trial

  19. AMG 479

    Takeda

    Adenocarcinoma of the Pancreas

    phase 3 small molecule completed

    1 trial

  20. AMIKACINE VIATRIS 1 g, poudre pour solution injectable en flacon, CHLORURE DE SODIUM 0,9 % COOPER, solution pour perfusion

    Tour Hekla

    Patients with ventilator-associated tracheobronchitis

    phase 3 small molecule active

    1 trial

  21. AMX0035, PL1 Oral powder in sachet, oral use

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 small molecule active

    1 trial

  22. ANAGRELIDE HYDROCHLORIDE MONOHYDRATE, PEGINTERFERON ALFA-2A, MK-3543, BUSULFAN, MK-3543, RUXOLITINIB, MK-3543, MK-3543, RUXOLITINIB, PEGINTERFERON ALFA-2A

    Merck Sharp and Dohme

    Essential Thrombocythemia patients who have an inadequate response to or are intolerant of hydroxyurea

    phase 3 small molecule active

    1 trial

  23. ANHYDROUS DOCETAXEL, FLUOROURACIL, FLUOROURACIL, OXALIPLATIN, CALCIUM LEVOFOLINATE

    CERO THERAPEUTICS HOLDINGS, INC.

    Locally advanced or metastatic oesogastric adenocarcinoma

    phase 3 small molecule active

    1 trial

  24. APF530

    Heron Therapeutics

    Chemotherapy-induced Nausea and Vomiting

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources